Total Payments
$344,790
2024 Payments
$46,450
Companies
31
Transactions
423
Medicare Patients
1,072
Medicare Billing
$249,688
Payment Breakdown by Category
Consulting$116,856 (33.9%)
Research$113,189 (32.8%)
Travel$56,486 (16.4%)
Other$38,792 (11.3%)
Food & Beverage$14,270 (4.1%)
Education$5,198 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $116,856 | 49 | 33.9% |
| Unspecified | $113,189 | 112 | 32.8% |
| Travel and Lodging | $56,486 | 105 | 16.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $32,620 | 24 | 9.5% |
| Food and Beverage | $14,270 | 123 | 4.1% |
| Honoraria | $6,000 | 3 | 1.7% |
| Education | $5,198 | 6 | 1.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $172.00 | 1 | 0.0% |
Payments by Type
General
$231,602
311 transactions
Research
$113,189
112 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $160,974 | 171 | $0 (2024) |
| Exelixis Inc. | $35,849 | 56 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $16,418 | 26 | $0 (2021) |
| Eisai Inc. | $16,111 | 20 | $0 (2020) |
| EMD Serono, Inc. | $13,388 | 12 | $0 (2021) |
| Astellas Pharma Global Development | $11,627 | 21 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $10,006 | 12 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $9,289 | 13 | $0 (2020) |
| Genentech USA, Inc. | $9,164 | 14 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $9,094 | 17 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,450 | 50 | PFIZER INC. ($42,604) |
| 2023 | $44,410 | 50 | PFIZER INC. ($42,541) |
| 2022 | $35,540 | 43 | Exelixis Inc. ($17,031) |
| 2021 | $24,021 | 24 | PFIZER INC. ($12,270) |
| 2020 | $44,082 | 33 | PFIZER INC. ($9,260) |
| 2019 | $61,364 | 78 | PFIZER INC. ($15,825) |
| 2018 | $55,696 | 97 | PFIZER INTERNATIONAL LLC ($15,502) |
| 2017 | $33,227 | 48 | PFIZER INC. ($6,100) |
All Payment Transactions
423 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/04/2024 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 11/21/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/09/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/13/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/10/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/10/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/14/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/13/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/29/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $1,400.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/02/2024 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: PF06821497 CLINICAL PUBLICATION PROGRAM | ||||||
| 08/02/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $143.09 | General |
| Category: ONCOLOGY | ||||||
| 08/02/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $87.10 | General |
| Category: HORMONE THERAPY | ||||||
| 07/24/2024 | Exelixis Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,165.20 | General |
| 07/17/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/28/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALZENNA CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/17/2024 | PFIZER INC. | TALZENNA (Drug) | Travel and Lodging | In-kind items and services | $550.79 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2024 | PFIZER INC. | TALZENNA (Drug) | Travel and Lodging | In-kind items and services | $309.00 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2024 | PFIZER INC. | TALZENNA (Drug) | Food and Beverage | In-kind items and services | $104.79 | General |
| Category: ONCOLOGY | ||||||
| 06/12/2024 | Exelixis Inc. | — | Travel and Lodging | Cash or cash equivalent | $1,643.93 | General |
| 06/02/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/02/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/02/2024 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/02/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug) | Food and Beverage | In-kind items and services | $167.07 | General |
| Category: PROSTATE CANCER DIAGNOSIS | ||||||
| 06/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $174.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $64,700 | 57 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $24,430 | 19 |
| TALZENNA CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,890 | 9 |
| AXITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,352 | 5 |
| PCYC-1128-CA | Pharmacyclics LLC, An AbbVie Company | $2,258 | 2 |
| Real-world characteristics and first-line treatment patterns of U.S. insured patients with metastatic castration-sensitive prostate cancer (mCSPC) | Astellas Pharma Global Development | $1,347 | 2 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $1,033 | 5 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| Real-world treatment patterns in patients with metastatic castration-sensitive prostate cancer in the US | Astellas Pharma Global Development | $402.17 | 4 |
| PF06821497 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| IMPLEMENT | Astellas Pharma Global Development | $308.20 | 1 |
| Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy | Astellas Pharma Global Development | $301.00 | 1 |
| IMPACT OF ENZALUTAMIDE ENZA VS. BICALUTAMIDE BIC ON HEALTH-R | Astellas Pharma Global Development | $184.00 | 2 |
| Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study | Astellas Pharma Global Development | $114.13 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 254 | 564 | $166,718 | $53,011 |
| 2022 | 3 | 255 | 643 | $183,196 | $61,279 |
| 2021 | 4 | 298 | 671 | $189,426 | $68,331 |
| 2020 | 2 | 265 | 806 | $238,043 | $67,068 |
Total Patients
1,072
Total Services
2,684
Medicare Billing
$249,688
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 177 | 434 | $138,214 | $44,375 | 32.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 44 | $13,894 | $4,439 | 31.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 18 | 18 | $8,034 | $2,542 | 31.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 28 | 68 | $6,576 | $1,654 | 25.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 176 | 510 | $153,865 | $51,839 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 52 | $15,675 | $5,470 | 34.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $7,750 | $2,440 | 31.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 25 | 63 | $5,905 | $1,530 | 25.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 192 | 541 | $158,297 | $59,102 | 37.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 36 | $10,534 | $3,948 | 37.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 49 | 56 | $12,152 | $2,775 | 22.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $6,028 | $1,899 | 31.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 12 | 24 | $2,416 | $607.64 | 25.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 203 | 717 | $209,794 | $58,632 | 27.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 46 | 73 | $21,360 | $6,259 | 29.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $6,889 | $2,177 | 31.6% |
About Dr. Neeraj Agarwal, MD
Dr. Neeraj Agarwal, MD is a Internal Medicine healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1417078221.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neeraj Agarwal, MD has received a total of $344,790 in payments from pharmaceutical and medical device companies, with $46,450 received in 2024. These payments were reported across 423 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($116,856).
As a Medicare-enrolled provider, Agarwal has provided services to 1,072 Medicare beneficiaries, totaling 2,684 services with total Medicare billing of $249,688. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Salt Lake City, UT
- Active Since 04/02/2007
- Last Updated 10/16/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1417078221
Products in Payments
- TALZENNA (Drug) $94,824
- XTANDI (Drug) $42,556
- Lenvima (Drug) $16,111
- INLYTA (Drug) $15,210
- Cabometyx (Drug) $10,947
- TECENTRIQ (Biological) $9,206
- Xofigo (Drug) $7,722
- OPDIVO (Biological) $6,155
- Erleada (Drug) $5,535
- Bavencio (Biological) $5,334
- IMFINZI (Drug) $5,252
- FOUNDATIONACT (Device) $4,542
- Non-Covered Product (Drug) $3,960
- LYNPARZA (Drug) $3,507
- VOTRIENT (Drug) $3,352
- CABOMETYX (Drug) $2,977
- Bavencio (Drug) $2,910
- JEVTANA (Drug) $2,783
- ERLEADA (Drug) $2,575
- ENZALUTAMIDE (Drug) $2,556
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Salt Lake City
Dr. Willard Dere, M.d, M.D
Internal Medicine — Payments: $5.4M
Internal Medicine $5.4M
Dr. Catherine Bakewell, M.d, M.D
Internal Medicine — Payments: $1.0M
Internal Medicine $1.0M
Dr. April Erwin, Md, MD
Internal Medicine — Payments: $381,757
Internal Medicine $381,757
George Rodgers, M.d, M.D
Internal Medicine — Payments: $229,629
Internal Medicine $229,629
James Chamberlain, Md, MD
Internal Medicine — Payments: $200,257
Internal Medicine $200,257
Schickwann Tsai, M.d, M.D
Internal Medicine — Payments: $122,681
Internal Medicine $122,681